论文部分内容阅读
由新型冠状病毒（2019-nCoV）感染导致的新型冠状病毒肺炎（COVID-19）已在全球范围暴发，虽积极救治，但仍有大量的重症患者，临床治疗压力巨大。恢复期血浆疗法利用感染后康复患者血浆中的特异性抗体治疗疾病，已在历史上多种重大传染病疫情中发挥作用，但也存在一定的局限性。目前尚无特效药物治疗的COVID-19，临床已在尝试使用恢复期血浆疗法并取得了一定疗效。本文通过讨论恢复期血浆疗法的历史、机制及在SARS等病毒性疾病中的应用经验，为恢复期血浆疗法在COVID-19的临床应用提供参考。“,”Coronavirus Disease 2019(COVID-19) caused by 2019-nCoV was in an outbreak globally. A large number of severe cases lead to strong clinical pressure even treated actively. Convalescent plasma (CP) therapy refers to a therapy infusing plasma from recovered donors into other infected individuals. It has played an important role in conquering variety of epidemics over a century with some limitations. Considering the absence of specific treatments, CP has been used for treating COVID-19 and achieved some efficacies. This article provides a reference for clinical application of CP therapy in COVID-19, by discussing the history, mechanism and application of CP therapy in viral diseases such as SARS.